Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2009; 15(35): 4415-4422
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4415
Table 1 Definition of complications
ComplicationICD-9-CMProcedure codesTreatment
Anemia281.xx, 283.xx, 284.xx, 285.xx
Alopecia704.0x, A9282
Asthenia780.7xHCPCS codes G9029-G9032
Constipation546.0xTherapeutic class 150-156
Cough786.2x, 786.3x, 786.4xTherapeutic class 128, 131
Dehydration276.50, 276.51
Dermatitis693.0x, 693.8x, 693.9x
Diarrhea007.xx, 009.x, 787.91Therapeutic class 148
Esophagitis530.1x
Fever780.6x
Gastritis535.xx
Headache784.0x
Infection001.xx-018.xx, 030.xx-041.xx, 045.xx-057.xx,Therapeutic class 2-20
070.xx-079.xx,
110.xx-118.xx, 130.xx-136.xx, 480.xx-486.xx, 995.91, 995.92
Insomnia780.51, 780.52Therapeutic class 74, Eszopiclone, Zaleplon, Zolpidem Tartrate
Mucositis528.0x, 528.1x , 528.2x, 528.3x, 528.6, 529.0x, 054.2x
Nausea and vomiting787.0x,CPT codes G9022, G9023, G9024, orTherapeutic class 160
HCPCS codes for antiemetics
Neutropenia288.0xHCPCS codes for neutropenia treatment
Night sweats780.8x
Weight loss783.2x, 783.0x
Complications of vascular access devices999.3x, 996.62, 996.74, 512.0x, 512.1x, 512.8x, 287.4x
Table 2 Baseline demographic and clinical characteristics1 of eligible patients with GEC by index treatment regimen (mean ± SD) n (%)
5-FU (n = 257)CAP (n = 105)5-FU combination (n = 344)CAP combination (n = 76)Any 5-FU (n = 540)Any CAP (n = 166)Total (n = 1013)1
Demographics2
Female180 (70.0)77 (73.3)264 (76.7)61 (80.3)395 (73.2)127 (76.5)746 (73.6)
Mean age (yr)63.2 (12.1)63.6 (12.4)60.3 (11.6)60.4 (12.0)61.7 (11.9)63.0 (12.3)62.6 (11.8)
Covered by Medicare127 (49.4)50 (47.6)126 (36.6)30 (39.5)231 (42.8)78 (47.0)465 (45.9)
Residing in urban area202 (78.6)83 (79.1)259 (75.3)64 (84.2)416 (77.0)136 (81.9)784 (77.4)
Clinical characteristics3
CCI5.5 (3.2)5.9 (3.0)4.9 (3.0)5.1 (3.1)5.1 (3.1)5.5 (3.0)5.2 (3.1)
CDS4.2 (3.5)4.5 (3.7)4.6 (3.4)4.3 (3.5)4.4 (3.4)4.6 (3.6)4.6 (3.5)
Metastatic disease4161 (62.7)55 (52.4)248 (72.1)47 (61.8)364 (67.4)97 (58.4)675 (66.6)
Previous treatment
Surgery125 (48.6)27 (25.7)46 (13.4)11 (14.5)154 (28.5)34 (20.5)239 (23.6)
Radiotherapy115 (44.8)25 (23.8)162 (47.1)15 (19.7)252 (46.7)40 (24.1)410 (40.5)
Baseline expenditure ($)55479 (4730)4965 (6277)4598 (5019)4178 (4005)5014 (5061)4607 (5573)4763 (5193)
Table 3 Distribution of patients by chemotherapy regimen and treatment setting 1n (%)
Chemotherapy regimenNeoadjuvant (n = 84)Adjuvant (n = 213)First-line (n = 743)Second-line (n = 354)Any setting (n = 1013)
All 5-FU-based regimens51 (60.7)140 (65.7)319 (42.9)139 (39.3)540 (53.5)
5-FU monotherapy16 (19.0)104 (48.8)89 (12.0)68 (19.2)257 (25.4)
5-FU + platinum24 (28.6)19 (8.9)104 (14.0)25 (7.1)163 (16.1)
5-FU + platinum + non-platinum14 (16.7)18 (8.5)96 (12.9)31 (8.8)145 (14.3)
5-FU + non-platinum2 (2.4)5 (2.3)30 (4.0)40 (11.3)73 (7.2)
Capecitabine-based regimens4 (4.8)24 (11.3)90 (12.1)72 (20.3)166 (16.4)
Capecitabine monotherapy2 (2.4)18 (8.5)50 (6.7)42 (11.9)105 (10.4)
Capecitabine + platinum2 (2.4)1 (0.5)11 (1.5)8 (2.3)19 (1.9)
Capecitabine + platinum + non-platinum0 (0.0)6 (2.8)16 (2.2)11 (3.1)31 (3.1)
Capecitabine + non-platinum0 (0.0)1 (0.5)13 (1.7)19 (5.4)32 (3.2)
Table 4 Frequency of complications (rate per 1000 person-months) in patients with GEC, by treatment regimen
Complication5-FU monotherapyCapecitabine monotherapy5-FU combination therapyCapecitabine combination therapyAny 5-FU regimenAny capecitabine regimen
Bone marrow233110349205307151
Constitutional symptom254108323295293183
Gastrointestinal tract symptoms465183577284529224
Infection199114268150238131
Skin complications002010
Other141422321922
Any complication764336835460806387